ZBH

Zimmer Biomet Holdings Inc

Add to Watchlist

Advanced Chart

92.180

+3.11(3.492%)1D

Line

Candle

YTD

High

92.990

Open

89.480

VWAP

91.85

Vol

2.55M

Mkt Cap

18.27B

Low

89.360

Amount

234.43M

EV/EBITDA(TTM)

9.64

Total Shares

205.73M

25.10B

EV/OCF(TTM)

14.89

P/S(TTM)

2.29

Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

2.18B

+4.98%

2.116

+2.24%

2.07B

+8.18%

1.920

+6.09%

2.22B

+9.94%

2.397

+3.75%

Estimates Revision

The market is revising Downward the revenue expectations for Zimmer Biomet Holdings, Inc. (ZBH) for FY2025, with the revenue forecasts being adjusted by -0.12% over the past three months. During the same period, the stock price has changed by -14.42%.

Revenue Estimates for FY2025

Revise Downward

-0.12%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.16%

In Past 3 Month

Stock Price

Go Down

-14.42%

In Past 3 Month

20 Analyst Rating

13.13% Upside

Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 104.28 USD with a low forecast of 88.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

12 Hold

2 Sell

Hold

13.13% Upside

Current: 92.180

Low

88.00

Averages

104.28

High

130.00

13.13% Upside

Current: 92.180

Low

88.00

Averages

104.28

High

130.00

Canaccord

Hold

downgrade

$101 -> $93

2025-11-10

Reason

Canaccord

Price Target

$101 -> $93

2025-11-10

downgrade

Hold

Reason

Canaccord lowered the firm's price target on Zimmer Biomet to $93 from $101 and keeps a Hold rating on the shares. The firm updated its model following Q3 results and subsequent 10Q release. They noted the company tightened its guidance and reiterated reported growth of 6.7-7.7% with the FNA acquisition expected to contribute roughly 270bps to growth.

Baird

Outperform

NULL

downgrade

$125 -> $117

2025-11-06

Reason

Baird

Price Target

$125 -> $117

2025-11-06

downgrade

Outperform

NULL

Reason

Baird lowered the firm's price target on Zimmer Biomet to $117 from $125 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results and although frustrated, are sticking with the name.

UBS

Danielle Antalffy

Sell

downgrade

$96 -> $88

2025-11-06

Reason

UBS

Danielle Antalffy

Price Target

$96 -> $88

2025-11-06

downgrade

Sell

Reason

UBS analyst Danielle Antalffy lowered the firm's price target on Zimmer Biomet to $88 from $96 and keeps a Sell rating on the shares.

Stifel

Rick Wise

Buy

downgrade

$118 -> $110

2025-11-05

Reason

Stifel

Rick Wise

Price Target

$118 -> $110

2025-11-05

downgrade

Buy

Reason

Stifel analyst Rick Wise lowered the firm's price target on Zimmer Biomet to $110 from $118 and keeps a Buy rating on the shares. The firm says the company's Q3 performance was frustratingly more mixed than it anticipated. While Zimmer did make positive progress on multiple fronts, at the same time, management highlighted that several end-of-quarter Q3 international and noncore business headwinds pressured sales by about 120bps. Stifel thinks that the quarter also illustrated Zimmer Biomet's commercial and innovation progress, factors that are not being considered in today's stock performance.

JPMorgan

Robbie Marcus

Overweight -> Neutral

downgrade

$100

2025-11-05

Reason

JPMorgan

Robbie Marcus

Price Target

$100

2025-11-05

downgrade

Overweight -> Neutral

Reason

JPMorgan analyst Robbie Marcus downgraded Zimmer Biomet to Neutral from Overweight with a $100 price target.

JPMorgan

Overweight -> Neutral

downgrade

$115 -> $100

2025-11-05

Reason

JPMorgan

Price Target

$115 -> $100

2025-11-05

downgrade

Overweight -> Neutral

Reason

JPMorgan downgraded Zimmer Biomet to Neutral from Overweight with a price target of $100, down from $115. The firm views the earnings report as a "step backwards" for Zimmer. Estimates are numbers moving lower due to a "mismatch" between management guidance and the underlying business trends, the analyst tells investors in a research note. JPMorgan says Zimmer's 2025 organic sales growth guidance is moving lower, and likely to is Street 2026 forecasts. It cites the reduced growth outlook for the downgrade.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zimmer Biomet Holdings Inc (ZBH.N) is 10.98, compared to its 5-year average forward P/E of 16.00. For a more detailed relative valuation and DCF analysis to assess Zimmer Biomet Holdings Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

16.00

Current PE

10.98

Overvalued PE

18.87

Undervalued PE

13.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

12.35

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

14.32

Undervalued EV/EBITDA

10.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.31

Current PS

0.00

Overvalued PS

3.89

Undervalued PS

2.73

Financials

Annual

Quarterly

FY2025Q3

YoY :

+9.71%

2.00B

Total Revenue

FY2025Q3

YoY :

+6.72%

341.40M

Operating Profit

FY2025Q3

YoY :

-7.22%

231.20M

Net Income after Tax

FY2025Q3

YoY :

-5.69%

1.16

EPS - Diluted

FY2025Q3

YoY :

-13.65%

267.70M

Free Cash Flow

FY2025Q3

YoY :

+1.43%

63.24

Gross Profit Margin - %

FY2025Q3

YoY :

+9.46%

14.12

FCF Margin - %

FY2025Q3

YoY :

-15.45%

11.55

Net Margin - %

FY2025Q3

YoY :

-26.52%

5.18

ROIC

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

156.2K

USD

3-6

Months

248.7K

USD

6-9

Months

150.7K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

93.8K

Volume

0-12

Months

988.3K

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

689.7K

Volume

Months

0-12

1.2M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

16.0K

USD

0-12

Months

16.0K

USD

Bought

0-3

0.0

USD

Months

3-6

16.0K

USD

Months

6-9

8.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

156.2K

USD

3-6

Months

248.7K

USD

6-9

Months

150.7K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ZBH News & Events

Events Timeline

2025-11-14 (ET)

2025-11-14

07:32:17

Zimmer Biomet receives FDA approval for ROSA Knee featuring OptimiZe.

2025-11-05 (ET)

2025-11-05

06:51:54

Zimmer Biomet reaffirms FY25 adjusted EPS forecast of $8.10-$8.30, in line with consensus of $8.14

2025-11-05

06:50:09

Zimmer Biomet announces Q3 adjusted EPS of $1.90, surpassing consensus estimate of $1.86

News

7.0

11-20PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zimmer Biomet Holdings, Inc. - ZBH

7.0

11-20Globenewswire

Bragar Eagel & Squire, P.C. Launches Investigation into Gauzy and Zimmer Biomet, Urging Investors to Reach Out to the Firm

7.0

11-19Globenewswire

Ongoing Securities Fraud Investigation of Zimmer Biomet Holdings, Inc. (ZBH) – Shareholders Who Suffered Losses Encouraged to Reach Out to The Law Offices of Frank R. Cruz